BridgeBio Pharma Inc
Statements
Ratios
Valuation ratios (P/E, P/S, EV/EBITDA and the other multiples) are based on the closing price at the end of each period, not on the current price. Margins and returns are shown in percent, multiples without a unit, per-share figures in the reporting currency, net debt in millions.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||||||||||||||||||||||||||
| – | – | – | – | – | – | – | 101.8 | 62.8 | 70.1 | 123.9 | 383.4 | 980.3 | 142.7 | 120.8 | 34.8 | 21.0 | 14.7 | 16.5 | 14.6 | 32.6 | 486.6 | 457.3 | 757.6 | 25.3 | 21.7 | 22.1 | 23.4 | 51.6 | 34.9 | 27.9 | 30.1 | 25.0 | 21.1 | |
| – | – | – | – | – | – | 5.5 | 10.1 | 9.0 | 14.4 | 27.1 | 146.1 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | 95.3 | 57.4 | 68.8 | 126.9 | 389.0 | 1,083.8 | 158.6 | 141.9 | 53.7 | 39.9 | 28.3 | 30.3 | 31.8 | 49.1 | 736.8 | 586.7 | 903.3 | 31.0 | 27.0 | 28.8 | 28.1 | 61.9 | 39.6 | 31.4 | 32.6 | 27.7 | 23.7 | |
| – | – | – | – | – | -8.6% | -9.1% | -6.3% | -8.4% | -8.0% | -8.7% | -4.8% | -5.5% | -5.3% | -7.4% | -22.5% | -37.3% | -37.1% | -32.0% | -37.5% | -16.1% | -17.7% | -11.5% | -7.5% | -11.0% | -8.8% | -9.5% | -10.2% | -7.7% | -8.1% | -6.0% | -3.0% | -3.1% | -4.1% | |
| Margins | ||||||||||||||||||||||||||||||||||
| – | – | – | – | – | – | – | – | – | – | – | – | – | 99.8% | 97.3% | 95.5% | 93.7% | 94.4% | 95.1% | 95.6% | 96.5% | 53.6% | 73.5% | 73.7% | 98.9% | 98.9% | 98.9% | 98.3% | 95.4% | 96.2% | 95.8% | 94.4% | 93.8% | 93.1% | |
| – | – | – | – | – | – | – | -656.4% | -560.8% | -662.4% | -1,190.1% | -2,150.1% | -6,193.3% | -811.3% | -945.5% | -827.1% | -821.5% | -627.5% | -618.7% | -659.6% | -597.4% | -9,350.0% | -5,931.1% | -6,528.8% | -220.0% | -232.9% | -250.0% | -267.2% | -547.6% | -278.4% | -172.4% | -113.3% | -98.4% | -78.6% | |
| – | – | – | – | – | – | – | -642.3% | -535.5% | -636.9% | -1,124.6% | -2,033.4% | -5,968.9% | -789.5% | -940.0% | -806.9% | -839.9% | -561.8% | -553.5% | -619.7% | -546.3% | -10,096.7% | -6,498.1% | -6,913.9% | -246.2% | -207.1% | -201.5% | -241.4% | -524.2% | -329.3% | -225.3% | -145.3% | -125.2% | -100.6% | |
| – | – | – | – | – | – | – | -637.9% | -525.1% | -560.7% | -1,081.4% | -1,845.4% | -5,413.4% | -760.9% | -892.3% | -783.4% | -782.2% | -546.3% | -528.1% | -548.4% | -525.4% | -8,600.5% | -5,280.2% | -5,686.6% | -277.1% | -191.5% | -209.5% | -238.7% | -399.8% | -283.1% | -168.2% | -91.1% | -78.3% | -85.6% | |
| Returns | ||||||||||||||||||||||||||||||||||
| – | – | – | – | -62.6% | – | -49.1% | -63.8% | -76.5% | -130.3% | -245.6% | -774.9% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | -28.1% | -39.3% | -60.6% | -35.2% | -41.2% | -29.4% | -38.3% | -51.1% | -63.8% | -47.6% | -45.8% | -68.5% | -55.5% | -73.3% | -59.1% | -67.3% | -77.2% | -67.9% | -113.8% | -93.5% | -117.7% | -63.4% | -57.1% | -66.0% | -58.3% | -75.8% | -71.9% | -79.9% | -77.9% | -52.9% | -57.2% | |
| Balance Sheet & Debt | ||||||||||||||||||||||||||||||||||
| – | – | – | – | -318 | -219 | -339 | -264 | -293 | -71 | 109 | 125 | 901 | 1,000 | 1,200 | 1,315 | 1,341 | 1,227 | 1,220 | 1,335 | 1,284 | 1,420 | 1,220 | 1,355 | 1,245 | 1,175 | 1,458 | 1,045 | 1,313 | 1,115 | 1,213 | 1,300 | 1,620 | 1,801 | |
| – | – | – | -35.3% | 62.8% | -97.1% | 71.8% | 64.7% | 38.5% | 29.4% | 20.8% | 8.2% | -36.2% | -42.9% | -95.1% | -85.9% | -128.0% | -118.9% | -156.2% | -201.4% | -195.9% | -270.4% | -184.4% | -247.9% | -123.6% | -137.6% | -185.0% | -159.7% | -187.0% | -165.5% | -193.6% | -221.9% | -165.5% | -206.6% | |
| – | – | – | – | 0.2 | – | 0.2 | 0.2 | 1.2 | 1.8 | 2.9 | 8.3 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| Per Share | ||||||||||||||||||||||||||||||||||
| – | – | – | -1.42 | -1.31 | -2.12 | -1.93 | -2.21 | -2.47 | -2.96 | -3.40 | -3.77 | -3.75 | -3.37 | -3.65 | -3.87 | -4.08 | -3.47 | -3.32 | -3.22 | -2.78 | -3.57 | -3.75 | -3.69 | -3.01 | -2.42 | -2.33 | -2.83 | -3.51 | -4.08 | -4.18 | -3.70 | -3.73 | -3.56 | |
| – | – | – | – | – | – | – | 0.34 | 0.46 | 0.46 | 0.30 | 0.19 | 0.06 | 0.43 | 0.39 | 0.48 | 0.49 | 0.62 | 0.60 | 0.52 | 0.51 | 0.04 | 0.06 | 0.05 | 1.22 | 1.17 | 1.16 | 1.17 | 0.67 | 1.24 | 1.86 | 2.55 | 2.98 | 3.53 | |
| 0.93 | – | – | -1.78 | 2.10 | -3.40 | 3.93 | 3.47 | 3.23 | 2.27 | 1.39 | 0.49 | -2.85 | -3.16 | -5.07 | -5.99 | -7.14 | -6.99 | -7.70 | -8.40 | -8.03 | -8.48 | -7.39 | -7.76 | -5.87 | -5.83 | -6.52 | -7.75 | -8.67 | -9.38 | -10.15 | -10.53 | -11.65 | -12.85 | |
| – | – | – | -1.68 | -1.53 | -2.33 | -1.95 | -2.20 | -2.42 | -2.61 | -3.27 | -3.42 | -3.40 | -3.25 | -3.46 | -3.76 | -3.80 | -3.38 | -3.16 | -2.85 | -2.68 | -3.04 | -3.05 | -3.03 | -3.39 | -2.24 | -2.42 | -2.80 | -2.68 | -3.50 | -3.12 | -2.32 | -2.33 | -3.02 | |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.